

# Paolo Simioni

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5623297/publications.pdf>

Version: 2024-02-01

449  
papers

15,342  
citations

32410

55  
h-index

29333

108  
g-index

457  
all docs

457  
docs citations

457  
times ranked

12538  
citing authors

#	ARTICLE	IF	CITATIONS
1	Tyrosine Kinase Inhibitor Sunitinib Delays Platelet-Induced Coagulation: Additive Effects of Aspirin. <i>Thrombosis and Haemostasis</i> , 2022, 122, 092-104.	1.8	11
2	The Neglected Role of Bile Duct Epithelial Cells in NASH. <i>Seminars in Liver Disease</i> , 2022, 42, 034-047.	1.8	8
3	Risk Factors for Post-Thrombotic Syndrome in Patients With a First Proximal Deep Venous Thrombosis Treated With Direct Oral Anticoagulants. <i>Angiology</i> , 2022, 73, 649-654.	0.8	6
4	Cardiac injury and COVID-19 associated coagulopathy in patients with acute SARS-CoV-2 pneumonia: A rotational thromboelastometry study. <i>Advances in Medical Sciences</i> , 2022, 67, 39-44.	0.9	4
5	Letter to the editor: Is PAI-1 a thrombotic biomarker in NASH cirrhosis?. <i>Hepatology</i> , 2022, 76, E16-E17.	3.6	1
6	Haemostatic alterations in patients with cirrhosis and hepatocellular carcinoma: laboratory evidence and clinical implications. <i>Liver International</i> , 2022, 42, 1229-1240.	1.9	17
7	Protein C or Protein S deficiency associates with paradoxically impaired platelet-dependent thrombus and fibrin formation under flow. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2022, 6, e12678.	1.0	2
8	Assessing Clinically Meaningful Hypercoagulability after COVID-19 Vaccination: A Longitudinal Study. <i>Thrombosis and Haemostasis</i> , 2022, 122, 1352-1360.	1.8	6
9	Risk Factors of Venous Thromboembolism in Noncritically Ill Patients Hospitalized for Acute COVID-19 Pneumonia Receiving Prophylactic-Dose Anticoagulation. <i>Viruses</i> , 2022, 14, 737.	1.5	7
10	Necroptosis-driving genes <i>RIPK1</i> , <i>RIPK3</i> and <i>MLKL</i> are associated with intratumoral CD3 <sup>+</sup> and CD8 <sup>+</sup> T cell density and predict prognosis in hepatocellular carcinoma. , 2022, 10, e004031.		27
11	Increased platelet aggregation in patients with decompensated cirrhosis indicates higher risk of further decompensation and death. <i>Journal of Hepatology</i> , 2022, 77, 660-669.	1.8	43
12	Intracranial Haemorrhage in Haemophilia Patients Is Still an Open Issue: The Final Results of the Italian EMO.REC Registry. <i>Journal of Clinical Medicine</i> , 2022, 11, 1969.	1.0	6
13	Impact of COVID-19 and COVID-19 vaccination on high-risk patients with antiphospholipid syndrome: a nationwide survey. <i>Rheumatology</i> , 2022, 61, S1136-S1142.	0.9	13
14	Global hemostatic profiling in patients with decompensated cirrhosis and bacterial infections. <i>JHEP Reports</i> , 2022, 4, 100493.	2.6	17
15	Systemic Catheter-Related Venous Thromboembolism in Children: Data From the Italian Registry of Pediatric Thrombosis. <i>Frontiers in Pediatrics</i> , 2022, 10, 843643.	0.9	7
16	Staging the pre-procedural prophylaxis in decompensated cirrhosis. <i>Digestive and Liver Disease</i> , 2022, 54, 1130-1132.	0.4	5
17	Mechanisms of thrombosis in pancreatic ductal adenocarcinoma. <i>Best Practice and Research in Clinical Haematology</i> , 2022, 35, 101346.	0.7	9
18	Exogenous human $\beta$ -Synuclein acts in vitro as a mild platelet antiaggregant inhibiting $\beta$ -thrombin-induced platelet activation. <i>Scientific Reports</i> , 2022, 12, .	1.6	4

#	ARTICLE	IF	CITATIONS
19	Translational Value of Tumor-Associated Lymphangiogenesis in Cholangiocarcinoma. <i>Journal of Personalized Medicine</i> , 2022, 12, 1086.	1.1	5
20	Reply to "Peripheral versus central venous blood sampling does not influence the assessment of platelet activation in cirrhosis". <i>Platelets</i> , 2022, 33, 1104-1106.	1.1	6
21	Microvesicles in bronchoalveolar lavage as a potential biomarker of COPD. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2021, 320, L241-L245.	1.3	18
22	Noninvasive Risk Stratification After HCV Eradication in Patients With Advanced Chronic Liver Disease. <i>Hepatology</i> , 2021, 73, 1275-1289.	3.6	45
23	Are thromboelastometric and thromboelastographic parameters associated with mortality in septic patients? A systematic review and meta-analysis. <i>Journal of Critical Care</i> , 2021, 61, 5-13.	1.0	14
24	Partial <i>F8</i> gene duplication (factor VIII Padua) associated with high factor VIII levels and familial thrombophilia. <i>Blood</i> , 2021, 137, 2383-2393.	0.6	20
25	Edoxaban for the Long-Term Therapy of Venous Thromboembolism: Should the Criteria for Dose Reduction be Revised?. <i>Clinical and Translational Science</i> , 2021, 14, 335-342.	1.5	0
26	Reduced Clot Stability by Thromboelastography as a Potential Indicator of Procedure-Related Bleeding in Decompensated Cirrhosis. <i>Hepatology Communications</i> , 2021, 5, 272-282.	2.0	35
27	Cardiopulmonary bypass-induced coagulopathy in pediatric patients: The role of platelets in postoperative bleeding. A preliminary study. <i>Artificial Organs</i> , 2021, 45, 852-860.	1.0	9
28	Thrombin generation in patients with COVID-19 with and without thromboprophylaxis. <i>Clinical Chemistry and Laboratory Medicine</i> , 2021, 59, 1323-1330.	1.4	40
29	The risk of arterial thrombosis in carriers of natural coagulation inhibitors: a prospective family cohort study. <i>Internal and Emergency Medicine</i> , 2021, 16, 997-1003.	1.0	6
30	Increased platelet aggregation in patients with cirrhosis and hepatocellular carcinoma: A new potential therapeutic target?. <i>Digestive and Liver Disease</i> , 2021, 53, S37-S38.	0.4	0
31	Influence of Hepatocellular Carcinoma on Platelet Aggregation in Cirrhosis. <i>Cancers</i> , 2021, 13, 1150.	1.7	21
32	Use of Glucocorticoids and Risk of Venous Thromboembolism: A Narrative Review. <i>Seminars in Thrombosis and Hemostasis</i> , 2021, 47, 654-661.	1.5	19
33	Hepatic benefits of HCV cure: Don't forget coagulation!. <i>Journal of Hepatology</i> , 2021, 74, 967-968.	1.8	5
34	PAR-4/Ca <sup>2+</sup> -calpain pathway activation stimulates platelet-derived microparticles in hyperglycemic type 2 diabetes. <i>Cardiovascular Diabetology</i> , 2021, 20, 77.	2.7	12
35	Determinants of increased thrombotic tendency in NASH cirrhosis: not there yet!. <i>Transplant International</i> , 2021, 34, 1325-1327.	0.8	1
36	Global reporting of pulmonary embolism-related deaths in the World Health Organization mortality database: Vital registration data from 123 countries. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2021, 5, e12520.	1.0	27

#	ARTICLE	IF	CITATIONS
37	Critical Review of the Evolution of Extracellular Vesicles™ Knowledge: From 1946 to Today. <i>International Journal of Molecular Sciences</i> , 2021, 22, 6417.	1.8	64
38	Coagulopathy is not predictive of bleeding in patients with acute decompensation of cirrhosis and acute-on-chronic liver failure. <i>Liver International</i> , 2021, 41, 2455-2466.	1.9	29
39	Acute kidney injury is associated with increased levels of circulating microvesicles in patients with decompensated cirrhosis. <i>Digestive and Liver Disease</i> , 2021, 53, 879-888.	0.4	17
40	More Pronounced Hypercoagulable State and Hypofibrinolysis in Patients With Cirrhosis With Versus Without HCC. <i>Hepatology Communications</i> , 2021, 5, 1987-2000.	2.0	16
41	Reply to "Acute kidney injury in patients with decompensated cirrhosis". <i>Digestive and Liver Disease</i> , 2021, 53, 1217-1218.	0.4	1
42	Absence of hypercoagulability after nCoV-19 vaccination: An observational pilot study. <i>Thrombosis Research</i> , 2021, 205, 24-28.	0.8	22
43	Comparison of Fondaparinux and Low-Molecular-Weight Heparin in the Treatment of Portal Vein Thrombosis in Cirrhosis. <i>American Journal of Medicine</i> , 2021, 134, 1278-1285.e2.	0.6	15
44	ABO blood groups and the risk of retinal vein occlusion. <i>Internal and Emergency Medicine</i> , 2021, 16, 1387-1390.	1.0	1
45	Post-operative hypercoagulable whole blood profiles in patients undergoing open thoracotomy vs video-assisted thoracoscopic surgery. <i>Blood Transfusion</i> , 2021, 19, 144-151.	0.3	4
46	Sounds Stimulation on In Vitro HL1 Cells: A Pilot Study and a Theoretical Physical Model. <i>International Journal of Molecular Sciences</i> , 2021, 22, 156.	1.8	12
47	Longitudinal Trend of Plasma Concentrations of Extracellular Vesicles in Patients Hospitalized for COVID-19. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 770463.	1.8	27
48	The prognostic role of ThromboDynamic Index in patients with severe sepsis. <i>Internal and Emergency Medicine</i> , 2020, 15, 163-168.	1.0	4
49	Changes in plasma circulating microvesicles in patients with HCV-related cirrhosis after treatment with direct-acting antivirals. <i>Liver International</i> , 2020, 40, 913-920.	1.9	12
50	Development of a Plasma-Based Assay to Measure the Susceptibility of Factor V to Inhibition by the C-Terminus of TFP1±. <i>Thrombosis and Haemostasis</i> , 2020, 120, 055-064.	1.8	4
51	Rivaroxaban compared with standard anticoagulants for the treatment of acute venous thromboembolism in children: a randomised, controlled, phase 3 trial. <i>Lancet Haematology</i> , 2020, 7, e18-e27.	2.2	173
52	Development and application of global assays of hyper- and hypofibrinolysis. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2020, 4, 46-53.	1.0	23
53	More Severe Hypercoagulable State in Acute COVID-19 Pneumonia as Compared With Other Pneumonia. <i>Mayo Clinic Proceedings Innovations, Quality &amp; Outcomes</i> , 2020, 4, 696-702.	1.2	12
54	COVID-19 "Associated Coagulopathy and Inflammatory Response: What Do We Know Already and What Are the Knowledge Gaps?. <i>Anesthesia and Analgesia</i> , 2020, 131, 1324-1333.	1.1	55

#	ARTICLE	IF	CITATIONS
55	COVID-19 and Venous Thromboembolism in Intensive Care or Medical Ward. <i>Clinical and Translational Science</i> , 2020, 13, 1108-1114.	1.5	46
56	Endothelial Damage of the Portal Vein is Associated with Heparin-Like Effect in Advanced Stages of Cirrhosis. <i>Thrombosis and Haemostasis</i> , 2020, 120, 1173-1181.	1.8	41
57	The hazard of (sub)therapeutic doses of anticoagulants in non-critically ill patients with Covid-19: The Padua province experience. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 2629-2635.	1.9	71
58	Platelet-primed interactions of coagulation and anticoagulation pathways in flow-dependent thrombus formation. <i>Scientific Reports</i> , 2020, 10, 11910.	1.6	21
59	Direct Oral Anticoagulants in Patients With Inherited Thrombophilia and Venous Thromboembolism: A Prospective Cohort Study. <i>Journal of the American Heart Association</i> , 2020, 9, e018917.	1.6	31
60	How haemophilia A impacts severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2) treatment: a case report. <i>Journal of Thrombosis and Thrombolysis</i> , 2020, 50, 795-798.	1.0	5
61	Different Hypercoagulable Profiles in Patients with COVID-19 Admitted to the Internal Medicine Ward and the Intensive Care Unit. <i>Thrombosis and Haemostasis</i> , 2020, 120, 1474-1477.	1.8	233
62	Acquired haemophilia A, concomitant acute myocardial infarction and urgent major surgery: How to successfully treat a critical patient with rFVIII (Obizur®). <i>Thrombosis Research</i> , 2020, 195, 125-127.	0.8	5
63	Viscoelastic testing in oncology patients (including for the diagnosis of fibrinolysis): Review of existing evidence, technology comparison, and clinical utility. <i>Transfusion</i> , 2020, 60, S86-S100.	0.8	6
64	Thrombin generation and thromboelastometry in monitoring the in-vitro reversal of warfarin: a comparison between 3-factor and 4-factor prothrombin complex concentrates. <i>Blood Coagulation and Fibrinolysis</i> , 2020, 31, 127-131.	0.5	4
65	Platelet-Derived Microparticles Bearing PF4 and Anti-GAGS Immunoglobulins in Patients with Sepsis. <i>Diagnostics</i> , 2020, 10, 627.	1.3	12
66	Incidence of VTE in asymptomatic children with deficiencies of antithrombin, protein C, and protein S: a prospective cohort study. <i>Blood Advances</i> , 2020, 4, 5442-5448.	2.5	7
67	Viscoelastic testing in benign hematologic disorders: Clinical perspectives and future implications of point-of-care testing to assess hemostatic competence. <i>Transfusion</i> , 2020, 60, S101-S121.	0.8	2
68	Anticoagulation resumption after intracranial hemorrhage in patients treated with VKA and DOACs. <i>European Journal of Internal Medicine</i> , 2020, 80, 73-77.	1.0	7
69	Acute Kidney Injury in Decompensated Cirrhosis Is Associated With Both Hypocoagulable and Hypercoagulable Features. <i>Hepatology</i> , 2020, 72, 1327-1340.	3.6	60
70	Thrombotic risk following video-assisted thoracoscopic surgery versus open thoracotomy: a systematic review and meta-analysis. <i>Interactive Cardiovascular and Thoracic Surgery</i> , 2020, 30, 573-581.	0.5	3
71	Acute kidney injury is associated with reversible platelet dysfunction in hospitalized patients with decompensated cirrhosis. <i>Digestive and Liver Disease</i> , 2020, 52, e13.	0.4	1
72	Heparin challenge test in patients undergoing cardiac surgery: dealing with heparin allergy. <i>Blood Coagulation and Fibrinolysis</i> , 2020, 31, 165-169.	0.5	0

#	ARTICLE	IF	CITATIONS
73	Increased Cardiovascular Risk Associated with Chemical Sensitivity to Perfluoro- $\alpha$ -Octanoic Acid: Role of Impaired Platelet Aggregation. <i>International Journal of Molecular Sciences</i> , 2020, 21, 399.	1.8	39
74	The haemostatic system in acromegaly: a single-centre case-control study. <i>Journal of Endocrinological Investigation</i> , 2020, 43, 1009-1018.	1.8	2
75	Immunization with Pentraxin3 prevents transition from subclinical to clinical lupus nephritis in lupus-prone mice: Insights from renal ultrastructural findings. <i>Journal of Autoimmunity</i> , 2020, 111, 102443.	3.0	7
76	COVID-19-Related Severe Hypercoagulability in Patients Admitted to Intensive Care Unit for Acute Respiratory Failure. <i>Thrombosis and Haemostasis</i> , 2020, 120, 998-1000.	1.8	553
77	MAC Project-Monitoring Anticoagulant Therapy Observational Study: Rationale and Protocol. <i>Frontiers in Medicine</i> , 2020, 7, 584459.	1.2	3
78	Absence of interaction between rivaroxaban, tacrolimus and everolimus in renal transplant recipients with deep vein thrombosis or atrial fibrillation. <i>Vascular Pharmacology</i> , 2020, 130, 106682.	1.0	10
79	Safety and efficacy of rivaroxaban in pediatric cerebral venous thrombosis (EINSTEIN-Jr CVT). <i>Blood Advances</i> , 2020, 4, 6250-6258.	2.5	49
80	Susoctocog-alfa (Obizur) in the treatment of nine elderly patients with acquired haemophilia A: an Italian multicentre real world experience. <i>Blood Transfusion</i> , 2020, 18, 312-321.	0.3	6
81	Whole-blood hypocoagulable profile correlates with a greater risk of death within 28 days in patients with severe sepsis. <i>Korean Journal of Anesthesiology</i> , 2020, 73, 224-231.	0.9	13
82	Cross-talk between coagulation and inflammation in COPD. The role of Factor XIII. , 2020, , .		0
83	Susoctocog-alfa (Obizur) in the treatment of nine elderly patients with acquired haemophilia A: an Italian multicentre real world experience. <i>Blood Transfusion</i> , 2020, , .	0.3	6
84	O007: Type of combined contraceptives and the risk of venous thromboembolism in antithrombin, protein C and protein S deficient women: a prospective cohort study. <i>Thrombosis Research</i> , 2019, 175, S3.	0.8	0
85	The relationship between pancreatic cancer and hypercoagulability: a comprehensive review on epidemiological and biological issues. <i>British Journal of Cancer</i> , 2019, 121, 359-371.	2.9	78
86	Bodyweight-adjusted rivaroxaban for children with venous thromboembolism (EINSTEIN-Jr): results from three multicentre, single-arm, phase 2 studies. <i>Lancet Haematology</i> , 2019, 6, e500-e509.	2.2	51
87	Enhanced fibrinolysis detection in a natural occurring canine model with intracavitary effusions: Comparison and degree of agreement between thromboelastometry and FDPs, D-dimer and fibrinogen concentrations. <i>PLoS ONE</i> , 2019, 14, e0225089.	1.1	3
88	SAT-115-Fondaparinux vs low molecular weight heparin in the treatment of non malignant portal vein thrombosis in patients with cirrhosis. <i>Journal of Hepatology</i> , 2019, 70, e681.	1.8	1
89	A prediction model for successful anticoagulation in cirrhotic portal vein thrombosis. <i>European Journal of Gastroenterology and Hepatology</i> , 2019, 31, 34-42.	0.8	58
90	Portal endothelial damage in cirrhosis. <i>Digestive and Liver Disease</i> , 2019, 51, e9-e10.	0.4	0

#	ARTICLE	IF	CITATIONS
91	Tailored prophylaxis with rFXIII (NovoThirteen <sup>®</sup> ) in a young girl with severe FXIII deficiency and previous cephalohaematoma. <i>Haemophilia</i> , 2019, 25, e206-e208.	1.0	2
92	Fondaparinux vs low molecular weight heparin in the treatment of non malignant portal vein thrombosis in patients cirrhosis. <i>Digestive and Liver Disease</i> , 2019, 51, e42.	0.4	2
93	Spontaneous recurrent intracranial haemorrhage in a woman with type 2B von Willebrand disease: A clinical case and a brief literature review. <i>Haemophilia</i> , 2019, 25, e282-e285.	1.0	2
94	Thrombophilia, risk factors and prevention. <i>Expert Review of Hematology</i> , 2019, 12, 147-158.	1.0	54
95	Patient blood management in cardiac surgery: The "Granducato algorithm". <i>International Journal of Cardiology</i> , 2019, 289, 37-42.	0.8	26
96	Thromboelastometry profiles after "in vitro" addition of a new plasma-derived factor V concentrate to whole blood from para haemophilia patients. <i>Haemophilia</i> , 2019, 25, e38-e42.	1.0	2
97	Levels of circulating microparticles in septic shock and sepsis-related complications: a case-control study. <i>Minerva Anestesiologica</i> , 2019, 85, 625-634.	0.6	26
98	Exosomes are differentially present in bronchoalveolar lavage (BAL) of smokers and patients with COPD and IPF. , 2019, , .		0
99	"In vitro" correction of the severe factor V deficiency-related coagulopathy by a novel plasma-derived factor V concentrate. <i>Haemophilia</i> , 2018, 24, 648-656.	1.0	18
100	Contact System Activation and Cancer: New Insights in the Pathophysiology of Cancer-Associated Thrombosis. <i>Thrombosis and Haemostasis</i> , 2018, 118, 251-265.	1.8	44
101	ABO blood group and the risk of post-thrombotic syndrome. <i>Annals of Hematology</i> , 2018, 97, 1057-1060.	0.8	7
102	Circulating microparticles in pregnant patients with primary anti-phospholipid syndrome: an exploratory study. <i>Scandinavian Journal of Rheumatology</i> , 2018, 47, 501-504.	0.6	5
103	On-treatment platelet reactivity in peripheral and coronary blood in patients undergoing primary PCI for ST-segment elevation myocardial infarction (STEMI). <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , 2018, 78, 281-286.	0.6	1
104	Clinical and laboratory characteristics of isolated lupus anticoagulants. <i>Thrombosis Research</i> , 2018, 165, 51-53.	0.8	9
105	Activated Platelet-Derived and Leukocyte-Derived Circulating Microparticles and the Risk of Thrombosis in Heparin-Induced Thrombocytopenia: A Role for PF4-Bearing Microparticles?. <i>Cytometry Part B - Clinical Cytometry</i> , 2018, 94, 334-341.	0.7	34
106	Cancer-Associated Thrombosis in Cirrhotic Patients with Hepatocellular Carcinoma. <i>Cancers</i> , 2018, 10, 450.	1.7	51
107	Association between ABO blood group and bleeding phenotype in patients with mild rare bleeding disorders. <i>Haemophilia</i> , 2018, 24, e428-e430.	1.0	3
108	Effect of sugammadex on coagulation as detected by rotational thromboelastometry in morbidly obese patients. <i>Minerva Anestesiologica</i> , 2018, 84, 178-188.	0.6	9

#	ARTICLE	IF	CITATIONS
109	Padua FIXa resistance to Protein S and a potential therapy for hyperactive FIXa. <i>Thrombosis Research</i> , 2018, 170, 133-141.	0.8	5
110	Peculiar laboratory phenotype/genotype relationship due to compound inherited protein C defects in a child with severe venous thromboembolism. <i>Hamostaseologie</i> , 2018, 38, 33-38.	0.9	2
111	Study of the endothelial dysfunction in patients with gastro-intestinal cancer: preliminary results. <i>Thrombosis Research</i> , 2018, 164, S226.	0.8	0
112	Circulating microparticles and thrombotic risk in patients with HCV-related cirrhosis who underwent DAA treatment. <i>Journal of Hepatology</i> , 2018, 68, S538-S539.	1.8	0
113	Predictors of cancer-associated thrombosis in gastro-intestinal cancer: preliminary results. <i>Thrombosis Research</i> , 2018, 164, S199-S200.	0.8	0
114	New generation flow-cytometry to measure circulating microvesicles in cancer. <i>Thrombosis Research</i> , 2018, 164, S242-S243.	0.8	0
115	The diagnostic challenge: are we missing pulmonary embolism diagnosis in patients with syncope?. <i>Internal and Emergency Medicine</i> , 2018, 13, 965-969.	1.0	0
116	Reversal of hypercoagulability in patients with HCV-related cirrhosis after treatment with direct-acting antivirals. <i>Liver International</i> , 2018, 38, 2210-2218.	1.9	39
117	Dabigatran in ibrutinib-treated patients with atrial fibrillation and lymphoproliferative diseases: Experience of 4 cases. <i>Hematological Oncology</i> , 2018, 36, 801-803.	0.8	4
118	The sudden and unexpected appearance of inhibitors in a previously treated severe haemophilia B patient after the switch to albutrepenonacog alpha. <i>Haemophilia</i> , 2018, 24, e372-e375.	1.0	5
119	Factor V Has Anticoagulant Activity in Plasma in the Presence of TFP1±: Difference between FV1 and FV2. <i>Thrombosis and Haemostasis</i> , 2018, 118, 1194-1202.	1.8	18
120	Hemostatic findings of pleural fluid in dogs and the association between pleural effusions and primary hyperfibrinogenolysis: A cohort study of 99 dogs. <i>PLoS ONE</i> , 2018, 13, e0192371.	1.1	6
121	Characterization of Microparticles in the lung of smokers. , 2018, , .		0
122	A Plasma-Based Assay to Measure the Susceptibility of Factor V(a) to Inhibition By TFP1±. <i>Blood</i> , 2018, 132, 1168-1168.	0.6	0
123	Paediatric venous thromboembolism: a report from the Italian Registry of Thrombosis in Children (RITI). <i>Blood Transfusion</i> , 2018, 16, 363-370.	0.3	7
124	Thromboelastometry hypercoagulable profiles and portal vein thrombosis in cirrhotic patients with hepatocellular carcinoma. <i>Digestive and Liver Disease</i> , 2017, 49, 440-445.	0.4	66
125	Screening and treatment of portal vein thrombosis in cirrhosis. <i>Digestive and Liver Disease</i> , 2017, 49, 228-229.	0.4	3
126	New functional assays to selectively quantify the activated protein C and tissue factor pathway inhibitor cofactor activities of protein S in plasma. <i>Journal of Thrombosis and Haemostasis</i> , 2017, 15, 950-960.	1.9	10



#	ARTICLE	IF	CITATIONS
127	Dual polarization of human alveolar macrophages progressively increases with smoking and COPD severity. <i>Respiratory Research</i> , 2017, 18, 40.	1.4	92
128	Modulating thrombotic diathesis in hereditary thrombophilia and antiphospholipid antibody syndrome: a role for circulating microparticles?. <i>Clinical Chemistry and Laboratory Medicine</i> , 2017, 55, 934-943.	1.4	5
129	The current understanding of trauma-induced coagulopathy (TIC): a focused review on pathophysiology. <i>Internal and Emergency Medicine</i> , 2017, 12, 981-991.	1.0	23
130	Thrombin generation tests and viscoelastic testing in cirrhosis. <i>European Journal of Anaesthesiology</i> , 2017, 34, 36-37.	0.7	1
131	Association between ascites and primary hyperfibrinolysis: A cohort study in 210 dogs. <i>Veterinary Journal</i> , 2017, 223, 12-20.	0.6	10
132	Prothrombotic microparticles and risk of portal vein thrombosis in patients with HCV-related liver cirrhosis who underwent DAA antiviral therapy. <i>Digestive and Liver Disease</i> , 2017, 49, e9.	0.4	0
133	Local prothrombotic state in portal venous system in cirrhosis. <i>Digestive and Liver Disease</i> , 2017, 49, e16.	0.4	0
134	Thromboelastographic evaluation of hemostatic balance in cirrhotic patients with infection. <i>Digestive and Liver Disease</i> , 2017, 49, e55.	0.4	1
135	Predictors of postoperative bleeding in children undergoing cardiopulmonary bypass: A preliminary Italian study. <i>Thrombosis Research</i> , 2017, 153, 85-89.	0.8	8
136	Albumin uptake in human podocytes: a possible role for the cubilin-amnionless (CUBAM) complex. <i>Scientific Reports</i> , 2017, 7, 13705.	1.6	38
137	miR-30c-5p regulates macrophage-mediated inflammation and pro-atherosclerosis pathways. <i>Cardiovascular Research</i> , 2017, 113, 1627-1638.	1.8	62
138	Decreased hypercoagulable state in hepatitis C virus-cirrhotic patients treated with DAA: the outcome revolution. <i>Journal of Hepatology</i> , 2017, 66, S122.	1.8	0
139	Hyperfibrinolysis during liver transplantation detected by classical parameters and thromboelastometry. <i>Journal of Hepatology</i> , 2017, 66, S195.	1.8	0
140	Hemostatic Findings in Ascitic Fluid: A Cross-sectional Study in 70 Dogs. <i>Journal of Veterinary Internal Medicine</i> , 2017, 31, 43-50.	0.6	6
141	Thromboelastometry guided fibrinogen replacement therapy in cardiac surgery: a retrospective observational study. <i>Journal of Anesthesia</i> , 2017, 31, 286-290.	0.7	14
142	Factor VIIa-antithrombin complex: a possible new biomarker for activated coagulation. <i>Clinical Chemistry and Laboratory Medicine</i> , 2017, 55, 484-488.	1.4	13
143	Circulating levels and characterization of microparticles in patients with different degrees of glucose tolerance. <i>Cardiovascular Diabetology</i> , 2017, 16, 118.	2.7	55
144	Factor V Leiden paradox and the occurrence of distal vein thrombosis in a large cohort of thrombotic patients. <i>Thrombosis Research</i> , 2017, 156, 20-22.	0.8	3

#	ARTICLE	IF	CITATIONS
145	Point-of-care management of fulminant hyperfibrinolysis in the Emergency Department after hanging trauma. <i>Anaesthesia Cases</i> , 2016, 4, 97-101.	0.0	1
146	Circulating microparticles and the risk of thrombosis in inherited deficiencies of antithrombin, protein C and protein S. <i>Thrombosis and Haemostasis</i> , 2016, 115, 81-88.	1.8	36
147	Cell Therapy for Parkinson's Disease: A Translational Approach to Assess the Role of Local and Systemic Immunosuppression. <i>American Journal of Transplantation</i> , 2016, 16, 2016-2029.	2.6	31
148	Thrombophilic risk of individuals with rare compound factor V Leiden and prothrombin G20210A polymorphisms: an international case series of 100 individuals. <i>European Journal of Haematology</i> , 2016, 97, 353-360.	1.1	10
149	Efficacy and safety of treatment of acute nonmalignant portal vein thrombosis with subcutaneous fondaparinux in patients with cirrhosis and marked thrombocytopenia. <i>Digestive and Liver Disease</i> , 2016, 48, e25-e26.	0.4	3
150	Circulating microparticles and risk of portal vein thrombosis in patients with liver cirrhosis and hepatocellular carcinoma. <i>Digestive and Liver Disease</i> , 2016, 48, e37.	0.4	0
151	New Prothrombin Mutation (Arg596Trp, Prothrombin Padua 2) Associated With Venous Thromboembolism. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2016, 36, 1022-1029.	1.1	49
152	Whole Blood Coagulation Tests are not Equally able to Detect Haemostatic Prothrombotic Alterations in Patients with Liver Cirrhosis and Hepatocellular Carcinoma: Rotational Thromboelastometry versus Thrombination Test. <i>Journal of Hepatology</i> , 2016, 64, S246.	1.8	0
153	Microparticles as biomarkers of venous thromboembolic events. <i>Biomarkers in Medicine</i> , 2016, 10, 743-755.	0.6	46
154	Endocytosis of exogenous factor V by <i>in vivo</i> differentiated megakaryocytes from patients with severe para haemophilia. <i>British Journal of Haematology</i> , 2016, 175, 517-524.	1.2	6
155	Diagnosis and management of factor V Leiden. <i>Expert Review of Hematology</i> , 2016, 9, 1139-1149.	1.0	39
156	Thromboelastometry profiles in patients undergoing thrombolytic therapy for acute ischaemic stroke. <i>Thrombosis and Haemostasis</i> , 2016, 115, 1231-1234.	1.8	12
157	Perioperative coagulation assessment of patients undergoing major elective orthopedic surgery. <i>Internal and Emergency Medicine</i> , 2016, 11, 793-801.	1.0	18
158	OC.03.7 CIRCULATING MICROPARTICLES AND RISK OF PORTAL VEIN THROMBOSIS IN PATIENTS WITH LIVER CIRRHOSIS AND HEPATOCELLULAR CARCINOMA. <i>Digestive and Liver Disease</i> , 2016, 48, e82.	0.4	0
159	Hypercoagulability detected by circulating microparticles in patients with hepatocellular carcinoma and cirrhosis. <i>Thrombosis Research</i> , 2016, 143, 118-121.	0.8	29
160	Short-term exposure to high levels of air pollution (nickel) and the risk of acute unprovoked proximal deep vein thrombosis in the legs. <i>Internal and Emergency Medicine</i> , 2016, 11, 159-162.	1.0	6
161	The Coagulative Profile of Cyanotic Children Undergoing Cardiac Surgery: The Role of Whole Blood Preoperative Thromboelastometry on Postoperative Transfusion Requirement. <i>Artificial Organs</i> , 2016, 40, 698-705.	1.0	18
162	Dynamics of circulating microparticles in obesity after weight loss. <i>Internal and Emergency Medicine</i> , 2016, 11, 695-702.	1.0	34

#	ARTICLE	IF	CITATIONS
163	Clinical Data of Neonatal Systemic Thrombosis. <i>Journal of Pediatrics</i> , 2016, 171, 60-66.e1.	0.9	54
164	New Functional Assays to Selectively Quantify APC- and TFPI-Cofactor Activities of Protein S in Plasma. <i>Blood</i> , 2016, 128, 717-717.	0.6	0
165	Synergistic antitumour activity of <sc>RAF</sc>265 and <sc>ZSTK</sc>474 on human <sc>TT</sc> medullary thyroid cancer cells. <i>Journal of Cellular and Molecular Medicine</i> , 2015, 19, 2244-2252.	1.6	23
166	Hypercoagulability in overweight and obese subjects who are asymptomatic for thrombotic events. <i>Thrombosis and Haemostasis</i> , 2015, 113, 85-96.	1.8	82
167	Paediatric arterial ischaemic stroke and cerebral sinovenous thrombosis. <i>Thrombosis and Haemostasis</i> , 2015, 113, 1270-1277.	1.8	28
168	Whole blood thromboelastometry profiles in women with preeclampsia. <i>Clinical Chemistry and Laboratory Medicine</i> , 2015, 53, 1793-8.	1.4	16
169	No evidence for increased platelet activation in patients with hepatitis B- or C-related cirrhosis and hepatocellular carcinoma. <i>Thrombosis Research</i> , 2015, 135, 292-297.	0.8	23
170	Bortezomib, C1-Inhibitor and Plasma Exchange Do Not Prolong the Survival of Multi-Transgenic GalT-KO Pig Kidney Xenografts in Baboons. <i>American Journal of Transplantation</i> , 2015, 15, 358-370.	2.6	23
171	Characterization of an apparently synonymous <i>F5</i> mutation causing aberrant splicing and factor V deficiency. <i>Haemophilia</i> , 2015, 21, 241-248.	1.0	22
172	Assessment of Bleeding Risk in Patients with Cirrhosis. <i>Current Hepatology Reports</i> , 2015, 14, 9-18.	0.4	3
173	Circulating microparticles in umbilical cord blood in normal pregnancy and pregnancy with preeclampsia. <i>Thrombosis Research</i> , 2015, 136, 427-431.	0.8	32
174	Detection of IgG anti-Domain I beta2 Glycoprotein I antibodies by chemiluminescence immunoassay in primary antiphospholipid syndrome. <i>Clinica Chimica Acta</i> , 2015, 446, 201-205.	0.5	38
175	Origin and levels of circulating microparticles in normal pregnancy: A longitudinal observation in healthy women. <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , 2015, 75, 487-495.	0.6	16
176	The clinical performance of a chemiluminescent immunoassay in detecting anti-cardiolipin and anti- $\beta$ 2 glycoprotein I antibodies. A comparison with a homemade ELISA method. <i>Clinical Chemistry and Laboratory Medicine</i> , 2015, 53, 1083-9.	1.4	32
177	Dalteparin for pregnant women with thrombophilia. <i>Lancet, The</i> , 2015, 385, 688-689.	6.3	2
178	Hypercoagulability detected by whole blood thromboelastometry (ROTEM <sup>®</sup> ) and impedance aggregometry (MULTIPLATE <sup>®</sup> ) in obese patients. <i>Thrombosis Research</i> , 2015, 135, 548-553.	0.8	59
179	Role of factor V Leiden polymorphism or G20210A prothrombin variant in patients with sudden sensorineural hearing loss: A meta-analysis of the literature. <i>Thrombosis Research</i> , 2015, 135, 565-567.	0.8	4
180	Levels of angiogenic proteins in plasma and platelets are not different between patients with hepatitis B/C-related cirrhosis and patients with cirrhosis and hepatocellular carcinoma. <i>Platelets</i> , 2015, 26, 577-582.	1.1	14

#	ARTICLE	IF	CITATIONS
181	Protein S As a Potential Treatment for FIX-Derived Deep Vein Thrombosis. <i>Blood</i> , 2015, 126, 2277-2277.	0.6	0
182	Could Hemorrhagic and Thrombotic Risk Due to Peg-Asparaginase be Identified By Coagulative Tests Using Fibtex and Antithrombin Levels? A Single Centre Study. <i>Blood</i> , 2015, 126, 2305-2305.	0.6	0
183	Influence of single nucleotide polymorphisms on thrombin generation in factor V Leiden heterozygotes. <i>Thrombosis and Haemostasis</i> , 2014, 111, 438-446.	1.8	17
184	Factor IX-Padua enhances the fibrinolytic resistance of plasma clots. <i>Thrombosis and Haemostasis</i> , 2014, 111, 226-232.	1.8	3
185	Management of severe bleeding in a ruptured extrauterine pregnancy. <i>Blood Coagulation and Fibrinolysis</i> , 2014, 25, 176-179.	0.5	7
186	Life-threatening coagulopathy and hypofibrinogenaemia induced by tigecycline in a patient with advanced liver cirrhosis. <i>European Journal of Gastroenterology and Hepatology</i> , 2014, 26, 681-684.	0.8	38
187	Short-term exposure to high levels of air pollution as a risk factor for acute isolated pulmonary embolism. <i>Thrombosis Research</i> , 2014, 134, 259-263.	0.8	23
188	Thrombin generation in Cushing's Syndrome: do the conventional clotting indices tell the whole truth?. <i>Pituitary</i> , 2014, 17, 68-75.	1.6	22
189	Does decreased fibrinolysis have a role to play in the development of non-neoplastic portal vein thrombosis in patients with hepatic cirrhosis?. <i>Internal and Emergency Medicine</i> , 2014, 9, 397-403.	1.0	15
190	Hypercoagulability in cirrhotic patients with hepatocellular carcinoma (HCC) and portal vein thrombosis (PVT). <i>Digestive and Liver Disease</i> , 2014, 46, e138.	0.4	0
191	Portal vein thrombosis in cirrhosis: Predictors of successful anticoagulation therapy. <i>Digestive and Liver Disease</i> , 2014, 46, e132.	0.4	1
192	OC.04.1 PROSPECTIVE EVALUATION OF THE CORRELATION BETWEEN HEMOSTATIC STATUS AND INCIDENCE OF PORTAL VEIN THROMBOSIS IN PATIENTS WITH LIVER CIRRHOSIS AND HEPATOCELLULAR CARCINOMA. <i>Digestive and Liver Disease</i> , 2014, 46, S11.	0.4	0
193	Hemostatic status and portal vein thrombosis (PVT) in cirrhotic patients with hepatocellular carcinoma (HCC). <i>Digestive and Liver Disease</i> , 2014, 46, e36.	0.4	0
194	O32 PROSPECTIVE EVALUATION OF THE CORRELATION BETWEEN HEMOSTATIC ALTERATIONS AND INCIDENCE OF PORTAL VEIN THROMBOSIS IN PATIENTS WITH LIVER CIRRHOSIS AND HEPATOCELLULAR CARCINOMA. <i>Journal of Hepatology</i> , 2014, 60, S14.	1.8	0
195	Circulating microparticles in carriers of prothrombin G20210A mutation. <i>Thrombosis and Haemostasis</i> , 2014, 112, 432-437.	1.8	14
196	The antiproliferative effects of ouabain and everolimus on adrenocortical tumor cells. <i>Endocrine Journal</i> , 2014, 61, 41-53.	0.7	32
197	Fibrinogen $\uparrow$ increases the sensitivity to activated protein C in normal and factor V Leiden plasma. <i>Blood</i> , 2014, 124, 1531-1538.	0.6	17
198	Evaluation of a procoagulant phospholipid functional assay as a routine test for measuring circulating microparticle activity. <i>Blood Coagulation and Fibrinolysis</i> , 2014, 25, 534-537.	0.5	20

#	ARTICLE	IF	CITATIONS
199	Antithrombin Plasma Levels and Fitem Determination in Children with Acute Lymphoblastic Leukemia Undergoing Asparaginase Treatment. <i>Blood</i> , 2014, 124, 5246-5246.	0.6	1
200	Thromboelastometry for guiding bleeding management of the critically ill patient: a systematic review of the literature. <i>Minerva Anestesiologica</i> , 2014, 80, 1320-35.	0.6	49
201	Secondary parenchymal and vascular changes after middle cerebral artery stroke in children. <i>Neuroradiology</i> , 2013, 55, 1259-1266.	1.1	0
202	Whole blood rotation thromboelastometry (ROTEM®) profiles in subjects with non-neoplastic portal vein thrombosis. <i>Thrombosis Research</i> , 2013, 132, e131-e134.	0.8	39
203	P-036 Changes in plasma levels of factor VIIa-antithrombin complex during normal pregnancy and in pre-eclampsia. <i>Thrombosis Research</i> , 2013, 131, S86.	0.8	0
204	Association between increased FVIIa-antithrombin complex/FVIIa ratio and pre-eclampsia. <i>Journal of Maternal-Fetal and Neonatal Medicine</i> , 2013, 26, 1352-1354.	0.7	4
205	Factor VIIa-antithrombin complexes in patients with non-neoplastic portal vein thrombosis with and without cirrhosis. <i>International Journal of Laboratory Hematology</i> , 2013, 35, 101-105.	0.7	7
206	235 PREDICTORS OF RESPONSE TO ANTICOAGULANT THERAPY FOR THE TREATMENT OF PORTAL VEIN THROMBOSIS (PVT) IN CIRRHOSIS PATIENTS. <i>Journal of Hepatology</i> , 2013, 58, S101.	1.8	2
207	Different Impact on the Coagulation System of Two Continuous Flow LVADs: Axial Versus Centrifugal Flow. <i>Journal of Heart and Lung Transplantation</i> , 2013, 32, S177.	0.3	0
208	Identification of a novel frameshift mutation causing a premature stop codon in a young Nigerian man with type I antithrombin deficiency. <i>Thrombosis Research</i> , 2013, 131, 463-465.	0.8	4
209	Thrombin Activatable Fibrinolysis inhibitor in Cancer Patients with and without Venous Thromboembolism. <i>Thrombosis Research</i> , 2013, 132, 484-486.	0.8	7
210	“Hypocoagulable” thromboelastography profiles in patients with cyanotic congenital heart disease: Facts or technical artifacts?. <i>International Journal of Cardiology</i> , 2013, 168, 2914.	0.8	8
211	High dose of human plasma-derived FVIII/VWF as first-line therapy in patients affected by acquired haemophilia A and concomitant cardiovascular disease: four case reports and a literature review. <i>Haemophilia</i> , 2013, 19, e50-3.	1.0	15
212	Thromboelastographic evaluation of coagulative profiles in pig-to-monkey kidney xenotransplantation. <i>Xenotransplantation</i> , 2013, 20, 89-99.	1.6	9
213	Antisense-based RNA therapy of factor V deficiency: in vitro and ex vivo rescue of a F5 deep-intronic splicing mutation. <i>Blood</i> , 2013, 122, 3825-3831.	0.6	17
214	Influence of proband's characteristics on the risk for venous thromboembolism in relatives with factor V Leiden or prothrombin G20210A polymorphisms. <i>Blood</i> , 2013, 122, 2555-2561.	0.6	9
215	Circulating microparticles of glial origin and tissue factor bearing in high-grade glioma: a potential prothrombotic role. <i>Thrombosis and Haemostasis</i> , 2013, 110, 378-385.	1.8	55
216	Factor IX activity/antigen ratio and the risk of first unprovoked venous thromboembolism. <i>Thrombosis and Haemostasis</i> , 2013, 109, 755-756.	1.8	2

#	ARTICLE	IF	CITATIONS
217	ABO blood groups and the risk of venous thrombosis in patients with inherited thrombophilia. <i>Blood Transfusion</i> , 2013, 11, 250-3.	0.3	32
218	Effect on Thrombin Generation of the "In Vitro" Addition of Low-Dose LMWH to Plasma of Healthy Pregnant and Nonpregnant Women. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2012, 18, 331-333.	0.7	7
219	Prothrombin Mutation Conveying Antithrombin Resistance. <i>New England Journal of Medicine</i> , 2012, 367, 1069-1070.	13.9	6
220	The efficacy and the risk of immunogenicity of FIX Padua (R338L) in hemophilia B dogs treated by AAV muscle gene therapy. <i>Blood</i> , 2012, 120, 4521-4523.	0.6	100
221	Thrombosis risk in purely obstetric APS. <i>Blood</i> , 2012, 119, 2435-2436.	0.6	2
222	Increased anticoagulant response to low-molecular-weight heparin in plasma from patients with advanced cirrhosis. <i>Journal of Thrombosis and Haemostasis</i> , 2012, 10, 1823-1829.	1.9	74
223	Circulating glial-derived and tissue factor bearing microparticles in patients with high grade glioma. <i>Thrombosis Research</i> , 2012, 129, S171-S172.	0.8	0
224	Factor VIIa-antithrombin complexes plasma levels in cancer patients with and without thrombosis. <i>Thrombosis Research</i> , 2012, 129, S174.	0.8	0
225	Factor VIIa-antithrombin complexes plasma levels in cancer patients with and without thrombosis. <i>Thrombosis Research</i> , 2012, 129, 818-819.	0.8	3
226	Reprint of: Factor VIIa-AT complex plasma levels and arterial thrombosis. <i>Thrombosis Research</i> , 2012, 130, 141.	0.8	3
227	Prospective evaluation of anticoagulation and transjugular intrahepatic portosystemic shunt for the management of portal vein thrombosis in cirrhosis. <i>Liver International</i> , 2012, 32, 919-927.	1.9	284
228	Anticoagulation for the treatment of thrombotic complications in patients with cirrhosis. <i>Liver International</i> , 2012, 32, 1465-1476.	1.9	55
229	Obstetric complications and pregnancy-related venous thromboembolism: The effect of low-molecular-weight heparin on their prevention in carriers of factor V Leiden or prothrombin G20210A mutation. <i>Thrombosis and Haemostasis</i> , 2012, 107, 477-484.	1.8	25
230	Circulating microparticles in carriers of factor V Leiden with and without a history of venous thrombosis. <i>Thrombosis and Haemostasis</i> , 2012, 108, 633-639.	1.8	27
231	Genetic modulation of the FVLeiden/normal FV ratio and risk of venous thrombosis in factor V Leiden heterozygotes. <i>Journal of Thrombosis and Haemostasis</i> , 2012, 10, 73-80.	1.9	11
232	Whole blood rotation thromboelastometry (ROTEM <sup>®</sup> ) in nine severe factor V deficient patients and evaluation of the role of intraplatelets factor V. <i>Haemophilia</i> , 2012, 18, 463-468.	1.0	24
233	Platelet factor V levels in moderate to severe congenital factor V deficiency. <i>Haemophilia</i> , 2012, 18, e53-5.	1.0	2
234	Studies on Coagulation Incompatibilities for Xenotransplantation. <i>Methods in Molecular Biology</i> , 2012, 885, 71-89.	0.4	12

#	ARTICLE	IF	CITATIONS
235	Varicella and Stroke in Children. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2011, 17, E127-E130.	0.7	15
236	OC-10 Effect of low molecular weight heparin (LMWH) on thrombin generation in cirrhotic patients. <i>Digestive and Liver Disease</i> , 2011, 43, S68.	0.4	0
237	Thrombophilic screening in young patients (<40years) with idiopathic ischemic stroke: A controlled study. <i>Thrombosis Research</i> , 2011, 127, 85-90.	0.8	19
238	Endothelial, platelet, and tissue factor-bearing microparticles in cancer patients with and without venous thromboembolism. <i>Thrombosis Research</i> , 2011, 127, 473-477.	0.8	122
239	Factor VIIa-antithrombin complexes in children with ischemic stroke. <i>Thrombosis Research</i> , 2011, 128, 303-304.	0.8	10
240	Factor VIIa-AT complex plasma levels and arterial thrombosis. <i>Thrombosis Research</i> , 2011, 128, 507.	0.8	1
241	0.10b Low-molecular-weight heparin for prevention of obstetric complications in carriers of factor V Leiden or PT-G20210A mutation. <i>Thrombosis Research</i> , 2011, 127, S128.	0.8	0
242	P.28 Factor V Leiden, PT-G20210A, MTHFR C677T mutations and the risk of implantation failure in women undergoing assisted reproductive procedures (IVF or ICSI). <i>Thrombosis Research</i> , 2011, 127, S135-S136.	0.8	2
243	P.50 Effect of low dose LMWH <i>in vitro</i> addition on thrombin generation potential in healthy pregnant and non pregnant women. <i>Thrombosis Research</i> , 2011, 127, S141.	0.8	0
244	186 EFFECT OF LOW MOLECULAR WEIGHT HEPARIN (LMWH) ON THROMBIN GENERATION IN CIRRHOTIC PATIENTS AT DIFFERENT STAGES OF LIVER DISEASE. <i>Journal of Hepatology</i> , 2011, 54, S79-S80.	1.8	1
245	188 THROMBIN GENERATION IN PATIENTS WITH PORTAL VEIN THROMBOSIS (PVT) WITH AND WITHOUT CIRRHOSIS. <i>Journal of Hepatology</i> , 2011, 54, S80.	1.8	0
246	Effects of Long-Term Administration of Recombinant Human Protein C in Xenografted Primates. <i>Transplantation</i> , 2011, 91, 161-168.	0.5	13
247	Factor V Leiden pseudo-homozygotes have a more pronounced hypercoagulable state than factor V Leiden homozygotes. <i>Journal of Thrombosis and Haemostasis</i> , 2011, 9, 864-867.	1.9	6
248	Homozygous F5 deep-intronic splicing mutation resulting in severe factor V deficiency and undetectable thrombin generation in platelet-rich plasma. <i>Journal of Thrombosis and Haemostasis</i> , 2011, 9, 959-968.	1.9	38
249	The hazard of comparing apples and oranges: The proper indication for the use of recombinant activated clotting factor VII in cardiac surgery. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2011, 142, 1588-1589.	0.4	3
250	Freedom Solo Stentless Aortic Valve: Quantitative and Qualitative Assessment of Thrombocytopenia. <i>Annals of Thoracic Surgery</i> , 2011, 92, 1935.	0.7	13
251	Increased thrombin generation in liver transplant recipients: Does immunosuppressive therapy play a role?. <i>Liver Transplantation</i> , 2011, 17, 347-348.	1.3	3
252	Impact of Persistent Antiphospholipid Antibodies on Risk of Incident Symptomatic Thromboembolism in Children: A Systematic Review and Meta-Analysis. <i>Seminars in Thrombosis and Hemostasis</i> , 2011, 37, 802-809.	1.5	50

#	ARTICLE	IF	CITATIONS
253	Gender and the Risk of Venous Thromboembolism. <i>Seminars in Thrombosis and Hemostasis</i> , 2011, 37, 193-198.	1.5	28
254	Outcome of Long-Term Prophylaxis After Cerebral Hemorrhage in a Patient With Severe Hemophilia B. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2011, 17, 535-538.	0.7	1
255	Similar hypercoagulable state and thrombosis risk in type I and type III protein S-deficient individuals from families with mixed type I/III protein S deficiency. <i>Haematologica</i> , 2010, 95, 1563-1571.	1.7	47
256	Residual platelet factor V ensures thrombin generation in patients with severe congenital factor V deficiency and mild bleeding symptoms. <i>Blood</i> , 2010, 115, 879-886.	0.6	121
257	Upper extremity deep vein thrombosis. <i>Internal and Emergency Medicine</i> , 2010, 5, 103-109.	1.0	38
258	Hereditary and acquired protein S deficiencies are associated with low TFPI levels in plasma. <i>Journal of Thrombosis and Haemostasis</i> , 2010, 8, 294-300.	1.9	69
259	Thrombin generation-based assays to measure the activity of the TFPI-protein S pathway in plasma from normal and protein S-deficient individuals. <i>Journal of Thrombosis and Haemostasis</i> , 2010, 8, 750-758.	1.9	47
260	Factor VIIa-antithrombin complexes in patients with arterial and venous thrombosis. <i>Thrombosis and Haemostasis</i> , 2010, 103, 1188-1192.	1.8	32
261	Reference values for thromboelastometry (ROTEM®) in cynomolgus monkeys ( <i>Macaca fascicularis</i> ). <i>Thrombosis Research</i> , 2010, 126, e294-e297.	0.8	20
262	PO-30 Procoagulant phospholipids in patients with venous thromboembolism and cancer. <i>Thrombosis Research</i> , 2010, 125, S174.	0.8	0
263	PO-43 Hypofibrinolysis in patients with venous thromboembolism and cancer. <i>Thrombosis Research</i> , 2010, 125, S177.	0.8	0
264	PO-56 Potential contribution of microparticles to the thrombotic risk in high grade glioma. <i>Thrombosis Research</i> , 2010, 125, S181.	0.8	0
265	PO-58 Endothelial circulating microparticles in thromboembolism and cancer. <i>Thrombosis Research</i> , 2010, 125, S181-S182.	0.8	0
266	Impact of Thrombophilia on Risk of Arterial Ischemic Stroke or Cerebral Sinovenous Thrombosis in Neonates and Children. <i>Circulation</i> , 2010, 121, 1838-1847.	1.6	383
267	Similar hypercoagulable state and thrombosis risk in type I and type III protein S-deficient individuals from mixed type I/III families. <i>Haematologica</i> , 2010, , .	1.7	2
268	D-Dimer Evaluation of Hemorrhagic Orbital Lymphangioma. <i>Journal of Pediatric Ophthalmology and Strabismus</i> , 2010, 47, 174-177.	0.3	0
269	Impact of Persistent Antiphospholipid Antibodies on Symptomatic Thromboembolism In Children: A Systematic Review & Meta-Analysis [Observational Studies]. <i>Blood</i> , 2010, 116, 3169-3169.	0.6	2
270	Sex-related type of venous thromboembolism in patients with and without thrombophilia. <i>Thrombosis and Haemostasis</i> , 2009, 102, 177-178.	1.8	2



#	ARTICLE	IF	CITATIONS
271	Potential Role of Thrombelastography in the Monitoring of Acquired Factor VIII Inhibitor Hemophilia A: Report on a 78-year-old Woman With Life-threatening Bleedings. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2009, 15, 470-476.	0.7	7
272	The Risk of Cancer Progression in Women With Gynecological Malignancies and Thrombophilic Polymorphisms: A Pilot Case-Control Study. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2009, 15, 535-539.	0.7	9
273	The role of antiphospholipid antibodies toward the protein C/protein S system in venous thromboembolic disease. <i>American Journal of Hematology</i> , 2009, 84, 594-596.	2.0	20
274	Advances in understanding the bleeding diathesis in factor V deficiency. <i>British Journal of Haematology</i> , 2009, 146, 17-26.	1.2	69
275	In vitro and in vivo effects of the carbon monoxide-releasing molecule, CORM-3, in the xenogeneic pig-to-primate context. <i>Xenotransplantation</i> , 2009, 16, 99-114.	1.6	31
276	X-Linked Thrombophilia with a Mutant Factor IX (Factor IX Padua). <i>New England Journal of Medicine</i> , 2009, 361, 1671-1675.	13.9	298
277	Screening for thrombophilia and antithrombotic prophylaxis in pregnancy: Guidelines of the Italian Society for Haemostasis and Thrombosis (SISET). <i>Thrombosis Research</i> , 2009, 124, e19-e25.	0.8	48
278	Thrombophilia and gestational VTE. <i>Thrombosis Research</i> , 2009, 123, S41-S44.	0.8	4
279	O5 Microparticles plasma levels in women with venous thromboembolism and cancer. <i>Thrombosis Research</i> , 2009, 123, S132.	0.8	0
280	P33 Whole blood coagulation thrombelastometry (ROTEM®) profile in 19 pregnant women. <i>Thrombosis Research</i> , 2009, 123, S148-S149.	0.8	0
281	Impact of Thrombophilia On Arterial Ischemic Stroke or Cerebral Venous Sinus Thromboses in Children: A Systematic Review & Meta-Analysis of Observational Studies.. <i>Blood</i> , 2009, 114, 3993-3993.	0.6	0
282	Procoagulant activity in children with community acquired pneumonia, pleural effusion and empyema. <i>Pediatric Pulmonology</i> , 2008, 43, 472-475.	1.0	22
283	The steady two-dimensional flow over a rectangular obstacle lying on the bottom. <i>Journal of Mathematical Analysis and Applications</i> , 2008, 342, 1467-1480.	0.5	5
284	Factor V Leiden is associated with more distal location of deep vein thrombosis of the leg. <i>Journal of Thrombosis and Haemostasis</i> , 2008, 6, 544-545.	1.9	11
285	Duration of anticoagulation and risk of recurrent thromboembolism in carriers of factor V Leiden or prothrombin mutation. <i>Journal of Thrombosis and Haemostasis</i> , 2008, 6, 2223-2224.	1.9	12
286	Cerebral sinus venous thrombosis with parenchymal infarcts in a newborn with severe haemophilia A and subdural haematomas. <i>Haemophilia</i> , 2008, 14, 1117-1121.	1.0	3
287	AN UPDATED CLASSIFICATION OF FACTOR XIII DEFECT. <i>British Journal of Haematology</i> , 2008, 77, 565-566.	1.2	7
288	Peculiar rocket profile in the electroimmunoassay of Protein-S-deficient plasma: a clue to diagnosis?. <i>International Journal of Laboratory Hematology</i> , 2008, 12, 109-111.	0.2	0

#	ARTICLE	IF	CITATIONS
289	Cerebral sinovenous thrombosis in children: Thrombophilia and clinical outcome. <i>Thrombosis Research</i> , 2008, 121, 589-591.	0.8	11
290	Whole blood rotation thrombelastometry in subjects undergoing vitamin K antagonist treatment: hypo- or hypercoagulable profiles?. <i>Thrombosis Research</i> , 2008, 122, 568-569.	0.8	12
291	Impact of Inherited Thrombophilia on Venous Thromboembolism in Children. <i>Circulation</i> , 2008, 118, 1373-1382.	1.6	268
292	Low plasma levels of tissue factor pathway inhibitor in patients with congenital factor V deficiency. <i>Blood</i> , 2008, 112, 3615-3623.	0.6	135
293	Low-Molecular-Weight Heparin versus Compression Stockings for Thromboprophylaxis after Knee Arthroscopy. <i>Annals of Internal Medicine</i> , 2008, 149, 73.	2.0	126
294	Thrombophilia as a predictor of persistent residual vein thrombosis. <i>Haematologica</i> , 2008, 93, 479-480.	1.7	25
295	Whole blood coagulation assessment using rotation thrombelastogram thromboelastometry in patients with acute deep vein thrombosis. <i>Blood Coagulation and Fibrinolysis</i> , 2008, 19, 355-360.	0.5	43
296	Peculiar whole blood rotation thromboelastometry (Rotem) profile in 40 sideropenic anaemia patients. <i>Thrombosis and Haemostasis</i> , 2008, 100, 1106-1110.	1.8	82
297	Peculiar whole blood rotation thromboelastometry (Rotem) profile in 40 sideropenic anaemia patients. <i>Thrombosis and Haemostasis</i> , 2008, 100, 1106-10.	1.8	21
298	Promoter Polymorphisms in the Plasma Glutathione Peroxidase ( GPx-3 ) Gene. <i>Stroke</i> , 2007, 38, 41-49.	1.0	128
299	The risk of recurrent venous thromboembolism after discontinuing anticoagulation in patients with acute proximal deep vein thrombosis or pulmonary embolism. A prospective cohort study in 1,626 patients. <i>Haematologica</i> , 2007, 92, 199-205.	1.7	686
300	Differential effects of high prothrombin levels on thrombin generation depending on the cause of the hyperprothrombinemia. <i>Journal of Thrombosis and Haemostasis</i> , 2007, 5, 971-979.	1.9	37
301	The G20210A prothrombin variant and the risk of venous thromboembolism or fetal loss in pregnant women: a family study. <i>Journal of Thrombosis and Haemostasis</i> , 2007, 5, 2193-2196.	1.9	12
302	High prevalence of inherited thrombophilia in "presumed peri-neonatal" ischemic stroke. <i>European Journal of Haematology</i> , 2007, 80, 071119183417002-???	1.1	27
303	Acute oppressive chest pain in a 66-year-old woman with a recent Amplatzer device closure of patent foramen ovale. <i>Internal and Emergency Medicine</i> , 2007, 2, 229-230.	1.0	0
304	Impact of Inherited Thrombophilia on Symptomatic Venous Thrombo-Embolism (VTE) in Children: A Systematic Review & Meta-Analysis of 37 Studies Including 2470 Pediatric Patients.. <i>Blood</i> , 2007, 110, 3189-3189.	0.6	1
305	Soluble endothelial protein C receptor (sEPCR) levels and venous thromboembolism in carriers of two dysfunctional protein C variants. <i>Thrombosis Research</i> , 2006, 117, 523-528.	0.8	21
306	Who should be tested for thrombophilia?. <i>Current Opinion in Hematology</i> , 2006, 13, 337-343.	1.2	13

#	ARTICLE	IF	CITATIONS
307	Thrombosis and Thrombophilia in Children: A Systematic Review. <i>Seminars in Thrombosis and Hemostasis</i> , 2006, 32, 724-728.	1.5	32
308	Inherited Thrombophilia and Venous Thromboembolism. <i>Seminars in Thrombosis and Hemostasis</i> , 2006, 32, 700-708.	1.5	62
309	Isolation and Characterization of an Antifactor VIII Antibody from a Patient with Acquired Hemophilia A and a Severe Hemorrhagic Syndrome. <i>Blood</i> , 2006, 108, 4073-4073.	0.6	0
310	The risk of recurrent venous thromboembolism in patients with inherited deficiency of natural anticoagulants antithrombin, protein C and protein S. <i>Haematologica</i> , 2006, 91, 695-8.	1.7	94
311	The effect of pre-eclampsia on the levels of coagulation and fibrinolysis factors in umbilical cord blood of newborns. <i>Blood Coagulation and Fibrinolysis</i> , 2005, 16, 177-181.	0.5	9
312	Effects of Long-term Administration of High-dose Recombinant Human Antithrombin in Immunosuppressed Primate Recipients of Porcine Xenografts. <i>Transplantation</i> , 2005, 80, 1501-1510.	0.5	29
313	Early cerebral sinovenous thrombosis in a child with acute lymphoblastic leukemia carrying the prothrombin G20210A variant. <i>Blood Coagulation and Fibrinolysis</i> , 2005, 16, 43-49.	0.5	6
314	An underestimated combination of opposites resulting in enhanced thrombotic tendency. <i>Blood</i> , 2005, 106, 2363-2365.	0.6	52
315	Megakaryocytes endocytose and subsequently modify human factor V in vivo to form the entire pool of a unique platelet-derived cofactor. <i>Journal of Thrombosis and Haemostasis</i> , 2005, 3, 450-456.	1.9	62
316	The incidence of venous thromboembolism in carriers of antithrombin, protein C or protein S deficiency associated with the HR2 haplotype of factor V: a family cohort study. <i>Journal of Thrombosis and Haemostasis</i> , 2005, 3, 1414-1420.	1.9	15
317	Expression of the normal factor V allele modulates the APC resistance phenotype in heterozygous carriers of the factor V Leiden mutation. <i>Journal of Thrombosis and Haemostasis</i> , 2005, 3, 2695-2702.	1.9	31
318	The long term clinical course of acute deep vein thrombosis of the arm: prospective cohort study. <i>BMJ: British Medical Journal</i> , 2004, 329, 484-485.	2.4	143
319	Selective modulation of proteinâ€¦C affinity for EPCR and phospholipids by Gla domain mutation. <i>FEBS Journal</i> , 2004, 272, 97-108.	2.2	36
320	Screening for thrombophilia in children: a puzzling decision with unclear implications. <i>Journal of Thrombosis and Haemostasis</i> , 2004, 2, 1193-1194.	1.9	8
321	The G20210A prothrombin gene mutation: is there room for screening families?. <i>Journal of Thrombosis and Haemostasis</i> , 2004, 2, 1487-1488.	1.9	16
322	Alterations in the Coagulation Profile in Renal Pig-to-Monkey Xenotransplantation. <i>American Journal of Transplantation</i> , 2004, 4, 335-345.	2.6	25
323	Risk of recurrent venous thromboembolism and thrombophilia: does discrepancy make complexity or vice versa?. <i>Journal of Thrombosis and Haemostasis</i> , 2003, 1, 16-18.	1.9	13
324	The PAI-I gene 4G/5G Polymorphism and Deep Vein Thrombosis in Patients with Inherited Thrombophilia. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2003, 9, 299-307.	0.7	64

#	ARTICLE	IF	CITATIONS
325	Appropriateness of choice and interpretation of tests for thrombophilic defects: a practical experience. <i>Clinica Chimica Acta</i> , 2003, 333, 191-193.	0.5	1
326	Folate status and homocysteine level in Italian patients aged under 60 on oral anticoagulant therapy. <i>Annals of Medicine</i> , 2003, 35, 140-144.	1.5	1
327	Recurrent thromboembolism in fertile women with venous thrombosis: incidence and risk factors. <i>Thrombosis and Haemostasis</i> , 2003, 90, 964-966.	1.8	7
328	Seasonal Variation in the Incidence of Deep Vein Thrombosis in Patients With Deficiency of Protein C or Protein S. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2002, 8, 231-237.	0.7	18
329	A matrix-assisted laser desorption/ionization time-of-flight based method for screening the 1691G → A mutation in the factor V gene. <i>Blood Coagulation and Fibrinolysis</i> , 2002, 13, 117-122.	0.5	10
330	Isolation and characterization of an antifactor V antibody causing activated protein C resistance from a patient with severe thrombotic manifestations. <i>Blood</i> , 2002, 99, 3985-3992.	0.6	37
331	Incidence of venous thromboembolism in asymptomatic family members who are carriers of factor V Leiden: a prospective cohort study. <i>Blood</i> , 2002, 99, 1938-1942.	0.6	95
332	The incidence of venous thromboembolism in thrombophilic children: a prospective cohort study. <i>Blood</i> , 2002, 100, 2403-2405.	0.6	101
333	Activated Protein C Resistance in Normal and Pre-Eclamptic Pregnancies. <i>Gynecologic and Obstetric Investigation</i> , 2002, 54, 145-149.	0.7	15
334	Residual Venous Thrombosis as a Predictive Factor of Recurrent Venous Thromboembolism. <i>Annals of Internal Medicine</i> , 2002, 137, 955.	2.0	457
335	Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. <i>Blood</i> , 2002, 100, 3484-3488.	0.6	1,617
336	Effect of delivery modalities on the physiologic inhibition system of coagulation of the neonate. <i>Thrombosis Research</i> , 2002, 105, 15-18.	0.8	26
337	Factor V Leiden and prothrombin gene mutation in inflammatory bowel disease in Mediterranean area. <i>Digestive and Liver Disease</i> , 2001, 33, 559-562.	0.4	21
338	A Dysfunctional Factor X (Factor X San Giovanni Rotondo) Present at Homozygous and Double Heterozygous Level: Identification of a Novel Microdeletion (delC556) and Missense Mutation (Lys408 → Asn) in the Factor X Gene. <i>Thrombosis Research</i> , 2001, 101, 219-230.	0.8	25
339	Long-Term Use of Oral Contraceptive Therapy in Women With the Prothrombin 20210 G-A Polymorphism Without Thrombotic Complications: A Study of 13 Women (12 Heterozygotes and 1 Homozygote). <i>Journal of Thrombosis and Haemostasis</i> , 2001, 1, 1078-1081.	0.784314	19
340	Pregnancy-related Recurrent Events in Thrombophilic Women with Previous Venous Thromboembolism. <i>Thrombosis and Haemostasis</i> , 2001, 86, 929-929.	1.8	23
341	Abnormal Propeptide Processing Resulting in the Presence of Two Abnormal Species of Protein C in Plasma. <i>Thrombosis and Haemostasis</i> , 2001, 86, 1017-1022.	1.8	10
342	Heterozygous carrier of G20210A prothrombin mutation used oral contraceptive treatment for 23 years without thrombotic events, and developed cerebral venous thrombosis 1 month after resumption of the medication at the age of 50. <i>Blood Coagulation and Fibrinolysis</i> , 2001, 12, 161-162.	0.5	1

#	ARTICLE	IF	CITATIONS
343	Phenotype and genotype expression in pseudohomozygous R2 factor V. <i>Blood</i> , 2001, 98, 1988-1990.	0.6	4
344	A highly polymorphic microsatellite in the factor V gene is an informative tool for the study of factor V-related disorders. <i>British Journal of Haematology</i> , 2001, 114, 868-870.	1.2	1
345	ProC Global: A New Automated Screening Assay for the Evaluation of Total Function of the Protein C System. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2001, 7, 351-355.	0.7	3
346	Postthrombotic Syndrome: Incidence, Prevention, and Management. <i>Seminars in Vascular Medicine</i> , 2001, 01, 071-080.	2.1	14
347	Abnormal propeptide processing resulting in the presence of two abnormal species of protein C in plasma: characterization of the dysfunctional protein C Padua3 (protein C(R-1L/propeptide)). <i>Thrombosis and Haemostasis</i> , 2001, 86, 1017-22.	1.8	0
348	Factor V Leiden mutation and the risk of venous thromboembolism in pregnant women. <i>Haematologica</i> , 2001, 86, 1305-9.	1.7	38
349	Clinical and laboratory expression of associated thrombophilic conditions (homozygous/heterozygous factor V Leiden mutation and heterozygous prothrombin variant 20210A) in an Italian family. <i>Blood Coagulation and Fibrinolysis</i> , 2000, 11, 379-384.	0.5	5
350	Antiplatelet Therapy and Other Interventions after Revascularisation Procedures in Patients with Peripheral Arterial Disease: a Meta-analysis. <i>European Journal of Vascular and Endovascular Surgery</i> , 2000, 19, 370-380.	0.8	62
351	Symptomatic combined homozygous factor XII deficiency and heterozygous factor V Leiden. <a href="mailto:luscaber@tin.it">luscaber@tin.it</a> . <i>Journal of Thrombosis and Thrombolysis</i> , 2000, 9, 271-275.	1.0	14
352	Risk for subsequent venous thromboembolic complications in carriers of the prothrombin or the factor V gene mutation with a first episode of deep-vein thrombosis. <i>Blood</i> , 2000, 96, 3329-3333.	0.6	127
353	Combinations of 4 mutations (FV R506Q, FV H1299R, FV Y1702C, PT 20210G/A) affecting the prothrombinase complex in a thrombophilic family. <i>Blood</i> , 2000, 96, 1443-1448.	0.6	54
354	State-of-the-Art-Review : Combined Heterozygous Plasminogen Deficiency and Factor V Leiden Defect in the Same Kindred. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2000, 6, 36-40.	0.7	10
355	State-of-the-Art Review : G to A 20210 Prothrombin Polymorphism and Venous Thrombosis: Simple Association or Causal Relationship?. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2000, 6, 135-138.	0.7	4
356	Risk for subsequent venous thromboembolic complications in carriers of the prothrombin or the factor V gene mutation with a first episode of deep-vein thrombosis. <i>Blood</i> , 2000, 96, 3329-3333.	0.6	4
357	Combinations of 4 mutations (FV R506Q, FV H1299R, FV Y1702C, PT 20210G/A) affecting the prothrombinase complex in a thrombophilic family. <i>Blood</i> , 2000, 96, 1443-1448.	0.6	0
358	Incidence of Venous Thromboembolism in Families with Inherited Thrombophilia. <i>Thrombosis and Haemostasis</i> , 1999, 81, 198-202.	1.8	312
359	The Risk of Fetal Loss in Family Members of Probands with Factor V Leiden Mutation. <i>Thrombosis and Haemostasis</i> , 1999, 82, 1237-1239.	1.8	50
360	State-of-the-Art Review: Low Incidence of Venous Thrombosis in Homozygous Patients with NT 20210 G to a Prothrombin Polymorphism. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 1999, 5, 205-207.	0.7	6

#	ARTICLE	IF	CITATIONS
361	Asymptomatic Homozygous nt 20210 G to A Prothrombin Polymorphism in Two Blood Donors Belonging to Two Different Kindreds. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 1999, 5, 48-51.	0.7	17
362	Phenotype and Genotype Expression in Pseudohomozygous Factor VLEIDEN. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 1999, 19, 336-342.	1.1	18
363	Prothrombin and the prothrombin 20210 G to A polymorphism: their relationship with hypercoagulability and thrombosis. <i>Blood Reviews</i> , 1999, 13, 205-210.	2.8	24
364	Two Additional Homozygous Patients for the 20210 Prothrombin Polymorphism with No Venous Thrombosis. <i>Thrombosis Research</i> , 1999, 96, 415-417.	0.8	15
365	The molecular genetics of familial venous thrombosis. <i>Best Practice and Research in Clinical Haematology</i> , 1999, 12, 479-503.	0.7	24
366	Low Rate of Venous Thromboembolism in Asymptomatic Relatives of Proband with Factor V Leiden Mutation. <i>Annals of Internal Medicine</i> , 1999, 130, 538.	2.0	15
367	Incidence of venous thromboembolism in families with inherited thrombophilia. <i>Thrombosis and Haemostasis</i> , 1999, 81, 198-202.	1.8	50
368	The incidence of venous thromboembolism in asymptomatic carriers of a deficiency of antithrombin, protein C, or protein S: a prospective cohort study. <i>Blood</i> , 1999, 94, 3702-6.	0.6	130
369	Prothrombin antigen levels in symptomatic and asymptomatic carriers of the 20210A prothrombin variant. <i>British Journal of Haematology</i> , 1998, 103, 1045-1050.	1.2	54
370	Hemorrhagic and thrombotic disorders due to factor V deficiencies and abnormalities: an updated classification. <i>Blood Reviews</i> , 1998, 12, 45-51.	2.8	16
371	Factor V Leiden (Activated Protein C Resistance) Versus Factor V Deficiency in Padua, Italy. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 1998, 4, 201-204.	0.7	1
372	Factor V variants, activated protein C resistance and venous thromboembolism. <i>Blood Coagulation and Fibrinolysis</i> , 1998, 9, 661-662.	0.5	1
373	Platelet-Derived Factor Va/VaLeiden Cofactor Activities Are Sustained on the Surface of Activated Platelets Despite the Presence of Activated Protein C. <i>Blood</i> , 1998, 91, 2818-2829.	0.6	68
374	Molecular Bases of Pseudo-homozygous APC Resistance: The Compound Heterozygosity for FV R506Q and a FV Null Mutation Results in the Exclusive Presence of FV Leiden Molecules in Plasma. <i>Thrombosis and Haemostasis</i> , 1998, 80, 403-406.	1.8	29
375	The Risk of Recurrent Venous Thromboembolism in Patients with an Arg506â†’Gln Mutation in the Gene for Factor V (Factor V Leiden). <i>New England Journal of Medicine</i> , 1997, 336, 399-403.	13.9	385
376	Increased Tissue Factor-initiated Prothrombin Activation as a Result of the Arg506 â†’ Gln Mutation in Factor VLEIDEN. <i>Journal of Biological Chemistry</i> , 1997, 272, 20721-20729.	1.6	47
377	Antiphospholipid Antibodies Do Not Seem to Be Associated With Deep Vein Thrombosis: A Case Control Study. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 1997, 3, 165-167.	0.7	0
378	Factor V antigen levels in APC resistance, in factor V deficiency and in combined APC resistance and factor V deficiency (pseudohomozygosity for APC resistance). <i>Blood Coagulation and Fibrinolysis</i> , 1997, 8, 245-248.	0.5	5

#	ARTICLE	IF	CITATIONS
379	ACCURACY OF TWO NEWLY DESCRIBED D-DIMER TESTS IN PATIENTS WITH SUSPECTED DEEP VENOUS THROMBOSIS. <i>Thrombosis Research</i> , 1997, 86, 93-99.	0.8	42
380	An In Vitro Analysis of the Combination of Hemophilia A and Factor VLEIDEN. <i>Blood</i> , 1997, 90, 3067-3072.	0.6	86
381	Recurrence of venous thromboembolism in patients with familial thrombophilia. <i>Archives of Internal Medicine</i> , 1997, 157, 2227-2232.	4.3	62
382	Upper-extremity deep vein thrombosis. Risk factors, diagnosis, and complications. <i>Archives of Internal Medicine</i> , 1997, 157, 57-62.	4.3	82
383	Venous and arterial thrombophilia. <i>Haematologica</i> , 1997, 82, 96-100.	1.7	19
384	Fibronectin and antithrombin as markers of pre-eclampsia in pregnancy. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 1996, 70, 33-39.	0.5	22
385	Complications of protein C deficiency in I pregnancy. <i>Journal of Obstetrics and Gynaecology</i> , 1996, 16, 244-245.	0.4	0
386	Pitfalls of protein C assays in patients with activated protein C resistance. <i>Blood Coagulation and Fibrinolysis</i> , 1996, 7, 712-713.	0.5	2
387	Homozygous patients with APC resistance may remain paucisymptomatic or asymptomatic during oral contraception. <i>Blood Coagulation and Fibrinolysis</i> , 1996, 7, 590-594.	0.5	17
388	A new global test for the evaluation of the protein C/protein S system. <i>Blood Coagulation and Fibrinolysis</i> , 1996, 7, 465-469.	0.5	16
389	Thromboembolic disease developing during oral contraceptive therapy in young females with antiphospholipid antibodies. <i>Blood Coagulation and Fibrinolysis</i> , 1996, 7, 497-501.	0.5	31
390	Hereditary protein C deficiency associated with riboflavin-responsive lipid storage myopathy. <i>European Journal of Neurology</i> , 1996, 3, 61-65.	1.7	7
391	91. Factor Va plays a major role in determining the fibrinolytic potential of a clot. <i>Fibrinolysis</i> , 1996, 10, 28.	0.5	2
392	Prothrombin fragment 1+2 and thrombin-antithrombin complex levels in patients with inherited APC resistance due to factor V Leiden mutation. <i>British Journal of Haematology</i> , 1996, 92, 435-441.	1.2	64
393	Frequency of Pregnancy-Related Venous Thromboembolism in Anticoagulant Factor-Deficient Women: Implications for Prophylaxis. <i>Annals of Internal Medicine</i> , 1996, 125, 955.	2.0	187
394	Prevalence of Antiphospholipid Antibodies and Lupus Anticoagulant in Juvenile Patients with Objectively Documented Deep-vein Thrombosis. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 1996, 2, 69-73.	0.7	5
395	An Antifibrinolytic Mechanism Describing the Prothrombotic Effect Associated with Factor VLeiden. <i>Journal of Biological Chemistry</i> , 1996, 271, 22949-22952.	1.6	74
396	Relevance of Inherited Risk Factors in Young Patients with Deep-Vein Thrombosis. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 1996, 2, 55-59.	0.7	3

#	ARTICLE	IF	CITATIONS
397	Mutations which Introduce Free Cysteine Residues in the Gla-Domain of Vitamin K Dependent Proteins Result in the Formation of Complexes with Î±1-Microglobulin. <i>Thrombosis and Haemostasis</i> , 1996, 75, 070-075.	1.8	23
398	The Risk of Abortion and Stillbirth in Antithrombin-, Protein C-, and Protein S-deficient Women. <i>Thrombosis and Haemostasis</i> , 1996, 75, 387-388.	1.8	182
399	“Pseudo Homozygous” Activated Protein C Resistance due to Double Heterozygous Factor V Defects (Factor V Leiden Mutation and Type I Quantitative Factor V Defect) Associated with Thrombosis: Report of Two Cases Belonging to Two Unrelated Kindreds. <i>Thrombosis and Haemostasis</i> , 1996, 75, 422-426.	1.8	67
400	Antiphospholipid Antibodies, Recurrent Thromboembolism, and Intensity of Warfarin Anticoagulation. <i>Thrombosis and Haemostasis</i> , 1996, 75, 859-859.	1.8	43
401	Deep Venous Thrombosis and Lupus Anticoagulant. <i>Thrombosis and Haemostasis</i> , 1996, 76, 187-189.	1.8	61
402	Hyperhomocysteinemia and Deep-Vein Thrombosis A Case-Control Study. <i>Thrombosis and Haemostasis</i> , 1996, 76, 0883-0886.	1.8	106
403	Compound heterozygous protein C deficiency resulting in the presence of only the beta-form of protein C in plasma. <i>Blood</i> , 1996, 88, 2101-2108.	0.6	18
404	"Pseudo homozygous" activated protein C resistance due to double heterozygous factor V defects (factor V Leiden mutation and type I quantitative factor V defect) associated with thrombosis: report of two cases belonging to two unrelated kindreds. <i>Thrombosis and Haemostasis</i> , 1996, 75, 422-6.	1.8	10
405	Oral contraceptive therapy causes an increased and not a decreased resistance to APC. <i>Blood Coagulation and Fibrinolysis</i> , 1995, 6, 143.	0.5	2
406	A protein S functional assay yields unsatisfactory results in patients with activated protein C resistance. <i>Blood Coagulation and Fibrinolysis</i> , 1995, 6, 286.	0.5	5
407	Anticardiolipin antibodies, functional protein S deficiency, and fetal loss. <i>American Journal of Hematology</i> , 1995, 48, 65-66.	2.0	1
408	Detection and characterization of seven novel protein S (PROS) gene lesions: evaluation of reverse transcript-polymerase chain reaction as a mutation screening strategy. <i>Blood</i> , 1995, 86, 2632-2641.	0.6	41
409	Factor V Leiden and Thrombophilia. <i>New England Journal of Medicine</i> , 1995, 332, 1381-1384.	13.9	10
410	Patients with APC Resistance Compared with Those with Other Clotting Inhibitor Deficiencies Show Later Onset of Venous Thrombosis During Oral Contraception. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 1995, 1, 274-276.	0.7	8
411	Coagulation and plasma fibronectin parameters in HELLP syndrome. <i>International Journal of Gynecology and Obstetrics</i> , 1995, 50, 263-268.	1.0	30
412	The Utility of Non-invasive Tests for Detection of Previous Proximal-vein Thrombosis. <i>Thrombosis and Haemostasis</i> , 1995, 73, 592-596.	1.8	28
413	Ischemic Stroke in Young Patients With Activated Protein C Resistance. <i>Stroke</i> , 1995, 26, 885-890.	1.0	87
414	Detection and characterization of seven novel protein S (PROS) gene lesions: evaluation of reverse transcript-polymerase chain reaction as a mutation screening strategy. <i>Blood</i> , 1995, 86, 2632-2641.	0.6	2



#	ARTICLE	IF	CITATIONS
415	Detection and characterization of seven novel protein S (PROS) gene lesions: evaluation of reverse transcript-polymerase chain reaction as a mutation screening strategy. <i>Blood</i> , 1995, 86, 2632-41.	0.6	3
416	Changing Features of Proximal Vein Thrombosis Over Time. <i>Angiology</i> , 1994, 45, 377-382.	0.8	9
417	Clotting inhibitors and fibronectin as potential markers in preeclampsia. <i>International Journal of Gynecology and Obstetrics</i> , 1994, 47, 215-221.	1.0	22
418	Childhood stroke associated with familial protein S deficiency. <i>Brain and Development</i> , 1994, 16, 241-245.	0.6	25
419	Evaluation of activated protein C resistance in stored plasma. <i>Lancet, The</i> , 1994, 343, 1288-1290.	6.3	12
420	Prolonged oral contraceptive therapy in a woman with an antithrombin III abnormality involving heparin binding (Type Ie) without thromboembolic complications. <i>Blood Coagulation and Fibrinolysis</i> , 1994, 5, 313-314.	0.5	4
421	Homozygous factor V-deficient patients show resistance to activated protein C whereas heterozygotes do not. <i>Blood Coagulation and Fibrinolysis</i> , 1994, 5, 825-827.	0.5	8
422	Acquired risk factors for deep-vein thrombosis in symptomatic outpatients. <i>Archives of Internal Medicine</i> , 1994, 154, 164-168.	4.3	36
423	A simple ultrasound approach for detection of recurrent proximal-vein thrombosis. <i>Circulation</i> , 1993, 88, 1730-1735.	1.6	310
424	Protein C, factor VII and prothrombin time as early markers of liver function recovery or failure after liver transplantation. <i>Blood Coagulation and Fibrinolysis</i> , 1993, 4, 863-867.	0.5	8
425	Are oral contraceptives a more important risk factor than pregnancy in women with congenital antithrombin III deficiency?. <i>Blood Coagulation and Fibrinolysis</i> , 1993, 4, 841-842.	0.5	1
426	Are oral contraceptives a more important risk factor than pregnancy in women with congenital antithrombin III deficiency?. <i>Blood Coagulation and Fibrinolysis</i> , 1993, 4, 841-842.	0.5	2
427	A novel dysfunctional protein C (Protein C Padua 2) associated with a thrombotic tendency: substitution of Cys for Arg <sup>1</sup> results in a strongly reduced affinity for binding of Ca <sup>++</sup> . <i>British Journal of Haematology</i> , 1993, 85, 521-527.	1.2	25
428	A family with an abnormal protein C and a thrombotic tendency. <i>Haematologia</i> , 1993, 25, 25-33.	0.2	2
429	Intra-cardial thrombosis with systemic and pulmonary embolism as main symptoms in a patient with protein S deficiency. <i>Blood Coagulation and Fibrinolysis</i> , 1992, 3, 485-488.	0.5	4
430	Oral contraceptives caused thrombosis in a monoovular twin with protein C deficiency, while the other, without medication, remained asymptomatic. <i>Blood Coagulation and Fibrinolysis</i> , 1992, 3, 119-120.	0.5	13
431	Combined inherited protein s and heparin co-factor II deficiency in a patient with upper limb thrombosis: A family study. <i>Thrombosis Research</i> , 1992, 67, 23-30.	0.8	7
432	Occurrence of arterial thrombosis in a cohort of patients with hereditary deficiency of clotting inhibitors. <i>Journal of Medicine</i> , 1992, 23, 61-74.	0.1	4

#	ARTICLE	IF	CITATIONS
433	The biological inertia of coumarin-induced pre-factors (so called PIVKAs). <i>Thrombosis Research</i> , 1991, 64, 627-628.	0.8	1
434	The biological inertia of coumarin-induced pre-factors (so called PIVKAs). <i>Thrombosis Research</i> , 1991, 65, 627-628.	0.8	0
435	The role of drugs, particularly oral contraceptives, in triggering thrombosis in congenital defects of coagulation inhibitors. <i>Blood Coagulation and Fibrinolysis</i> , 1991, 2, 673-678.	0.5	25
436	Letter to the editor: Spurious protein C deficiency due to antiphospholipid antibodies. <i>American Journal of Hematology</i> , 1991, 36, 299-300.	2.0	18
437	Heterozygous Protein C Deficiency Associated with Multiple Congenital Hemangiomas—A Case Report. <i>Angiology</i> , 1991, 42, 337-342.	0.8	2
438	Heterozygous Protein-S Deficiency: A Study of a Large Kindred. <i>Acta Haematologica</i> , 1990, 84, 162-168.	0.7	11
439	Hereditary heparin cofactor II deficiency and thrombosis. <i>Blood Coagulation and Fibrinolysis</i> , 1990, 1, 351-556.	0.5	22
440	Discrepancies between clotting and amidolytic assay in congenital clotting disorders. <i>Thrombosis Research</i> , 1990, 59, 701-702.	0.8	3
441	Deep vein thrombophlebitis of a leg in a young female with heterozygous protein C deficiency taking oral contraceptives. <i>Folia Haematologica: Internationales Magazin Für Klinische Und Morphologische Blutforschung</i> , 1990, 117, 443-5.	0.0	0
442	Hereditary heparin cofactor II deficiency and thrombosis: report of six patients belonging to two separate kindreds. <i>Blood Coagulation and Fibrinolysis</i> , 1990, 1, 351-6.	0.5	5
443	Partial gene deletion in a family with factor X deficiency. <i>Blood</i> , 1989, 73, 2123-2127.	0.6	22
444	Effects of Glycosaminoglycans and Protamine Chloridrate on Platelet Aggregation Induced by Collagen and Thrombin. <i>Angiology</i> , 1989, 40, 170-174.	0.8	7
445	Kinetics of Human Platelet Factor 4 in Rabbits Effect of Glycosaminoglycans and Protamine Sulfate. <i>Annals of the New York Academy of Sciences</i> , 1989, 556, 429-431.	1.8	0
446	Severe Arterial Cerebral Thrombosis in a Patient with Protein S Deficiency (Moderately Reduced Total) Tj ETQq0 0 0 rgBT /Overlock 10 Tf	1.8	69
447	The Relationship between Defective Heparin Cofactor Activities and Thrombotic Phenomena in AT III Abnormalities. <i>Thrombosis and Haemostasis</i> , 1988, 59, 121-121.	1.8	9
448	Unmet needs in basic and translational research in Cholangiocarcinoma. <i>Liver Cancer International</i> , 0, , .	0.2	0
449	Obstetric Antiphospholipid Syndrome. , 0, , .		0